Bluebird Bio’s disclosure Tuesday that two additional patients being treated with its gene therapy for sickle cell disease had been diagnosed with cancer has forced the company to suspend operations and raised fears of a broader impact across the gene therapy field.
The cases follow an earlier cancer diagnosis in December 2018, and are refocusing attention on whether there is a causal link with the therapy.
About the Author Reprints
